

Lifetime Probability of Developing and Dying from Cancer, 2014-2016

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All Sites*	40.1	2	21.3	5	38.7	3	18.4	5
Brain & ONS	0.7	145	0.5	188	0.5	183	0.4	238
Breast	0.1	750	<0.1	3,217	12.8	8	2.6	39
Colorectal	4.4	23	1.8	55	4.1	25	1.7	60
Esophagus	0.8	126	0.8	132	0.2	415	0.2	502
Hodgkin lymphoma	0.2	418	<0.1	2,588	0.2	510	<0.1	3,555
Kidney & renal pelvis	2.2	46	0.6	166	1.2	82	0.3	306
Larynx	0.5	189	0.2	529	0.1	786	<0.1	2,143
Leukemia	1.9	54	1.0	104	1.3	77	0.7	146
Liver & intrahepatic bile duct	1.4	69	1.0	98	0.6	162	0.5	186
Lung & bronchus	6.7	15	5.5	18	6.0	17	4.5	22
Melanoma of skin†	3.6	28	0.5	210	2.5	41	0.2	425
Myeloma	0.9	107	0.5	212	0.7	141	0.4	263
Non-Hodgkin lymphoma	2.4	41	0.8	124	1.9	52	0.6	157
Oral cavity & pharynx	1.7	60	0.4	238	0.7	141	0.2	538
Ovary	--	--	--	--	1.3	80	0.9	114
Pancreas	1.7	60	1.4	72	1.6	62	1.4	74
Prostate	11.6	9	2.4	41	--	--	--	--
Stomach	1.1	94	0.4	224	0.7	151	0.3	332
Testis	0.4	247	<0.1	5,015	--	--	--	--
Thyroid	0.7	144	0.1	1,724	1.9	52	0.1	1,399
Urinary bladder‡	3.9	26	0.9	107	1.2	85	0.3	289
Uterine cervix	--	--	--	--	0.6	159	0.2	453
Uterine corpus	--	--	--	--	3.1	33	0.6	159

*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic whites.

‡Includes invasive and in situ cancer cases.

Source: Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.7, National Cancer Institute, 2019.